Retatrutide associated with improved glycemic control and bodyweight reduction in type 2 diabetes
1. HbA1c and bodyweight reduction were greater in the retatrutide group compared to dulaglutide and placebo. 2. The effect of ...
Tag: diabetes mellitus
Orforglipron may be a safe and effective oral GLP-1 agonist for treatment of type 2 diabetes
1. Patients assigned to orforglipron experienced significant reductions in HbA1c, and body weight compared to other groups. 2. The majority ...
#VisualAbstract:Insulin icodec is more effective than insulin glargine for glycemic control
In this randomized controlled trial, weekly insulin icodec use resulted in better glycemic control than daily insulin glargine in patients with ...
Insulin icodec is more effective than insulin glargine for glycemic control
1. In this randomized controlled trial, weekly insulin icodec use resulted in better glycemic control than daily insulin glargine in ...
Once-weekly insulin icodec non-inferior to daily insulin glargine for patients with type 2 diabetes on basal-bolus regimens
1. At 26 weeks, the mean change in HbA1c was comparable between the weekly insulin icodec and daily glargine U100 ...
#VisualAbstract: A closed-loop system of insulin delivery is superior in glycemic control for children with type 1 diabetes
Click here to read this study in NEJM
Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients
1. A low-carbohydrate high-fat (LCHF) diet improved glycemic and weight control in patients with type two diabetes mellitus (T2DM) compared ...
Meta-analysis shows significant decrease in age-related macular degeneration risk with metformin use
1. In a systematic review and meta-analysis of observational studies on patients with diabetes, metformin use was associated with a ...
SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes
1. SGLT2 inhibitors reduced the risk of kidney disease progression by 37% overall, with comparable effects in patients with and ...
Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve diabetes outcomes but are not cost effective
1. For sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists to be used as first-line agents for type ...
